Background: Angiogenesis-angiostasis balance and leukocyte recruitment are influenced by different concentrations of distinct chemokines. Objective: To investigate the relative contribution of angiogenic and angiostatic CXC chemokines to the pathogenesis of idiopathic pulmonary fibrosis (IPF) and granulomatous lung diseases, we examined the in vitro production of an angiogenic chemokine (IL-8), and 2 angiostatic chemokines (IP-10 and MIG) by alveolar macrophages. Methods: Alveolar macrophages from 16 patients with granulomatous lung diseases [8 with sarcoidosis, 8 with extrinsic allergic alveolitis (EAA)], 16 patients with IPF, and 8 control subjects were cultured for 24 h. IL-8, IL-18, IP-10 and MIG in the culture supernatants were measured by a fluorescent bead-based multiplex technique. Results: In IPF patients, IL-8 was increased and correlated with bronchoalveolar lavage (BAL) neutrophils, whereas the levels of IP-10 and MIG were normal. In sarcoidosis and EAA patients, IL-8, IP-10, and MIG were all increased and IP-10 and MIG correlated with IL-18, a Th1 cytokine, and the percentage and number of BAL lymphocytes. Conclusions: The difference in the expression of CXC chemokines and a Th1 cytokine may contribute to the different immunopathogenesis, clinical course and responsiveness to treatment of these diseases.

Keywords:
Alveolar macrophage, Chemokine, Granulomatous lung disease, Idiopathic pulmonary fibrosis
1.
American Thoracic Society/European Respiratory Society: International multidisciplinary consensus classification of idiopathic interstitial pneumonias: general principles and recommendations. Am J Respir Crit Care Med 2002;165:277–304.
2.
Newman LS, Wasfi YS: Sarcoidosis. Prog Respir Res 2007;36:128–138.
3.
Vogelmeier C: Hypersensitivity pneumonitis. Prog Respir Res 2007;36:139–147.
4.
Singer AJ, Clark RA: Cutaneous wound healing. N Engl J Med 1999;341:738–746.
5.
Michael PK, et al: ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:2239–2242.
6.
Peao MND, et al: Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin. Anat Rec 1994;238:57–67.
7.
Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000;12:254–257.
8.
Strieter RM, et al: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348–27357.
9.
Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol 2001;2:108–115.
10.
Gasperini S, et al: Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 1999;162:4928–4937.
11.
Coughlin CM, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441–1452.
12.
American Thoracic Society/European Respiratory Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646–664.
13.
Tong ZH, et al: Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 2003;124:1526–1532.
14.
Fujimori Y, et al: The role of interleukin-8 in interstitial pneumonia. Respirology 2003;8:33–40.
15.
Car BD, et al: Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 1994;149:655–659.
16.
Ziegenhagen MW, et al: Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med 1998;157:762–768.
17.
Gadek JE, et al: Collagenase in the low respiratory tract of patients with idiopathic pulmonary fibrosis. N Engl J Med 1979;301:737–742.
18.
Hunninghake GW, Gadek JE, Lawley TJ: Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1981;68:259–269.
19.
Lynch JP 3rd, et al: Neutrophilic alveolitis in idiopathic pulmonary fibrosis: the role of interleukin-8. Am Rev Respir Dis 1992;145:1433–1143.
20.
Takeuchi M, et al: Elevated serum levels of CXCL9/monokine induced by interferon-γ and CXCL10/interferon-γ-inducible protein-10 in ocular sarcoidosis. Invest Ophthalmo Vis Sci 2006;47:1063–1068.
21.
Nance S, Cross R, Fitzpatrick E: Chemokine production during hypersensitivity pneumonitis. Eur J Immunol 2004;34:677–685.
22.
Antoniou KM, et al: Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 2006;130:982–988.
23.
Miotto D, et al: Expression of IFN-gamma-inducible protein, monocyte chemotactic proteins 1, 3, and 4, and eotaxin in TH1- and TH2-mediated lung diseases. J Allergy Clin Immunol 2001;107:664–670.
24.
Agostini C, et al: Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 1998;161:6413–6420.
25.
Strieter RM, et al: CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005;16:593–609.
26.
Keane MP, et al: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997;159:1437–1443.
27.
Keane MP: Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999;162:5511–5518.
28.
Keane MP: IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999;163:5686–5692.
29.
Ebina M, et al: Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;169:1203–1208.
30.
Meyer KC, Cardoni A, Xiang ZZ: Vascular endothelial growth factor in brochoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med 2000;135:332–338.
31.
Cosgrove GP, et al: Aberrant angiogenesis in idiopathic pulmonary fibrosis (abstract). Am J Respir Crit Care Med 2003;167:A300.
32.
Robert MS, John AB, Michael PK: CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest 2002;122:298–301.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.